Current approaches to HIV vaccine development: a narrative review
Introduction The development of an effective vaccine to protect against HIV is a longstanding
global health need complicated by challenges inherent to HIV biology and to the execution …
global health need complicated by challenges inherent to HIV biology and to the execution …
Controlling the SARS-CoV-2 spike glycoprotein conformation
R Henderson, RJ Edwards, K Mansouri… - Nature structural & …, 2020 - nature.com
The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary
immunogenic target for virus neutralization and the current focus of many vaccine design …
immunogenic target for virus neutralization and the current focus of many vaccine design …
A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
The development of a protective vaccine remains a top priority for the control of the HIV/AIDS
pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing …
pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing …
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice
The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-
19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope …
19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope …
Rapid and focused maturation of a VRC01-class HIV broadly neutralizing antibody lineage involves both binding and accommodation of the N276-glycan
Summary The VH1-2 restricted VRC01-class of antibodies targeting the HIV envelope CD4
binding site are a major focus of HIV vaccine strategies. However, a detailed analysis of …
binding site are a major focus of HIV vaccine strategies. However, a detailed analysis of …
New vaccine design and delivery technologies
M Kanekiyo, D Ellis, NP King - The Journal of Infectious …, 2019 - academic.oup.com
Technological advances in immunology, protein design, and genetic delivery have unlocked
new possibilities for vaccine concepts and delivery technologies that were previously …
new possibilities for vaccine concepts and delivery technologies that were previously …
Env exceptionalism: why are HIV-1 Env glycoproteins atypical immunogens?
PJ Klasse, G Ozorowski, RW Sanders, JP Moore - Cell host & microbe, 2020 - cell.com
Recombinant HIV-1 envelope (Env) glycoproteins of ever-increasing sophistication have
been evaluated as vaccine candidates for over 30 years. Structurally defined mimics of …
been evaluated as vaccine candidates for over 30 years. Structurally defined mimics of …
Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements
The trimeric HIV-1 Envelope protein (Env) mediates viral-host cell fusion via a network of
conformational transitions, with allosteric elements in each protomer orchestrating host …
conformational transitions, with allosteric elements in each protomer orchestrating host …